Lista de obras -

A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk

article

A model-based approach to sample size estimation in recent onset type 1 diabetes

artículo científico publicado en 2016

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history

artículo científico publicado en 2014

A pilot study showing associations between frequency of CD4(+) memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes

artículo científico publicado en 2016

A quantitative measure of treatment response in recent-onset type 1 diabetes

artículo científico publicado en 2020

Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes

artículo científico publicado en 2018

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

artículo científico publicado en 2019

Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes

artículo científico publicado en 2019

Biomarker discovery in pre-Type 1 Diabetes; Th40 cells as a predictive risk factor

scientific article published on 07 May 2019

Can non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?

artículo científico publicado en 2017

Comparison of two insulin assays for first-phase insulin release in type 1 diabetes prediction and prevention studies.

artículo científico publicado en 2011

Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report

artículo científico publicado en 2015

Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?

artículo científico publicado en 2016

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression

scientific article published on 20 March 2019

Effect of rituximab on human in vivo antibody immune responses ⬇️

artículo científico publicado el 9 de septiembre de 2011

Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes

artículo científico publicado en 2013

Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk

artículo científico publicado en 2015

Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236

artículo científico publicado en 2020

Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk

artículo científico publicado en 2018

Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents

scientific article published on 14 January 2020

Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?

artículo científico publicado en 2017

Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose

artículo científico publicado en 2016

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

artículo científico publicado en 2012

GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis

artículo científico publicado en 2016

HLA-DRB115:01-DQA101:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression

artículo científico publicado en 2016

Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective

artículo científico publicado en 2015

Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes

article

Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives

artículo científico publicado en 2017

Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests

artículo científico

Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis

artículo científico publicado en 2016

Recommendations for the definition of clinical responder in insulin preservation studies

artículo científico publicado en 2014

Response to Comment on: Greenbaum et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012;61:2066-2073.

artículo científico publicado en 2013

Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders

artículo científico publicado en 2014

Slowed Metabolic Decline after One Year of Oral Insulin Treatment among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 and TrialNet Oral Insulin Prevention Trials

scientific article published on 21 May 2020

TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes.

artículo científico publicado en 2017

Teplizumab in Relatives at Risk for Type 1 Diabetes. Reply

scientific article published on 01 November 2019

The Effect of Ethnicity in the Rate of Beta Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis

scientific article published on 05 June 2020

The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study

artículo científico publicado en 2020

The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus.

artículo científico publicado en 2016

The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults

artículo científico publicado en 2017

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results

artículo científico publicado en 2008

The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes

artículo científico publicado en 2012

The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis

artículo científico publicado en 2013

The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes

artículo científico publicado en 2015

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients

artículo científico publicado en 2013

The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants

artículo científico publicado en 2016

The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes

artículo científico publicado en 2017

The use of intermediate endpoints in the design of type 1 diabetes prevention trials

scientific article published on 07 June 2013

Transcription Factor 7-Like 2 () Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes

article

Type 1 Diabetes TrialNet--an international collaborative clinical trials network

artículo científico publicado en 2008

Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes

scientific article published on 08 August 2019

Update on worldwide efforts to prevent type 1 diabetes

artículo científico publicado en 2008

Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study

artículo científico publicado en 2017

Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention

artículo científico publicado en 2019

Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies

artículo científico publicado en 2012

β cell death and dysfunction during type 1 diabetes development in at-risk individuals

artículo científico publicado en 2015

Lista de obras de

A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk

A model-based approach to sample size estimation in recent onset type 1 diabetes

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history

A pilot study showing associations between frequency of CD4(+) memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes

A quantitative measure of treatment response in recent-onset type 1 diabetes

Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes

Biomarker discovery in pre-Type 1 Diabetes; Th40 cells as a predictive risk factor

Can non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?

Comparison of two insulin assays for first-phase insulin release in type 1 diabetes prediction and prevention studies.

Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report

Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression

Effect of rituximab on human in vivo antibody immune responses ⬇️

Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes

Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk

Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236

Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk

Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents

Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?

Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis

HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression

Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective

Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes

Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives

Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests

Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis

Recommendations for the definition of clinical responder in insulin preservation studies

Response to Comment on: Greenbaum et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012;61:2066-2073.

Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders

Slowed Metabolic Decline after One Year of Oral Insulin Treatment among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 and TrialNet Oral Insulin Prevention Trials

TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes.

Teplizumab in Relatives at Risk for Type 1 Diabetes. Reply

The Effect of Ethnicity in the Rate of Beta Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis

The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study

The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus.

The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results

The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes

The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis

The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients

The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants

The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes

The use of intermediate endpoints in the design of type 1 diabetes prevention trials

Transcription Factor 7-Like 2 () Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes

Type 1 Diabetes TrialNet--an international collaborative clinical trials network

Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes

Update on worldwide efforts to prevent type 1 diabetes

Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study

Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention

Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies

β cell death and dysfunction during type 1 diabetes development in at-risk individuals

HLA-DRB115:01-DQA101:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression